PETVIVO HOLDINGS, INC. LAUNCHES DIGITAL MEDIA CAMPAIGN
PetVivo Holdings announces a comprehensive digital media campaign to promote its product Spryng™, targeting improvements in animal lameness. The campaign includes 40 interviews and 600 T.V. commercials over the next year on major networks like Newsmax and Bloomberg. Additionally, 2,400 digital billboard ads will be displayed daily in Manhattan. Spryng™, which aids osteoarthritis in pets, is set for expanded sales this quarter. PetVivo aims to leverage veterinary opportunities similar to human therapies, supported by a robust patent portfolio.
- Launch of a digital media campaign to boost visibility for Spryng™.
- Scheduled for 600 commercials and 2,400 daily digital ads over the next year.
- Spryng™ targets a significant market need in treating osteoarthritis in pets.
- None.
MINNEAPOLIS, MN, US, Nov. 29, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (“PetVivo”), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, today announces the launch of a digital media campaign, which includes the production, broadcasting, and distribution of technical interviews, commercials and digital billboards ads. The digital media campaign was produced and organized by FMW Media Corp., the creator/producer of “New to The Street T.V.”.
The digital media campaign includes the production and broadcast of at least 40 interviews, as well as the production of 30-second T.V. commercials, wherein at least 50 commercials shall be broadcast per month, for a total of 600 commercials. For the next 12 months, the interviews and commercials shall air on Newsmax TV, Bloomberg, Fox Business Network, and CNBC. Additionally, the PetVivo will run at least two thousand four hundred (2400) 15-second commercial ads per day. These ads will be displayed on digital billboards that are located throughout lower Manhattan, New York City, NY.
“With New to The Street and their sophisticated media production staff and writers, we can develop a fantastic digital media message about PetVivo Holdings, Inc, and how the administration of Spryng™ can assist in addressing the debilitating effects of lameness in companion animals,” stated John Lai, Chief Executive Officer of PetVivo.
PetVivo’s innovative therapeutic product, Spryng, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural purified proteins, collagen and elastin. Spryng with OsteoCushion Technology provides both reinforcing natural joint support to replace and/or reinforce missing and damaged cartilage. These attributes delivered through one simple intraarticular injection offers a great solution to manage lameness afflictions, such as osteoarthritis, which is frequently found in companion animals.
https://drive.google.com/drive/folders/1As19iTSLz4KuDwHOrCPV3S4quG1kMbNL?usp=sharing
"New to The Street T.V. and our staff of dedicated professional look forward in the production and distribution of commercial and digital billboards designed to inform individuals and businesses about PetVivo and Spryng’s unique therapeutic capabilities to enhance the lives of companion animals and their owners,” stated Mr. Vincent Caruso, CEO of FMW Media Corp. “The combination of long-form monthly continuous television updates on the largest most-watched business networks including NEWSMAX, short-form commercials, and NYC outdoor and subway digital boards, can certainly inform the masses about PetVivo and Spryng."
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for animals. The Company's strategy is to leverage human therapies for the treatment of dogs and horses in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale in the fourth quarter of this year.
About FMW Media Corp:
FMW Media operates one of the longest-running U.S. and International sponsored and Syndicated Nielsen Rated programming T.V. brands, "New to the Street," and its blockchain show "Exploring The Block." Since 2009, these brands aired, produced, and distributed biographical interview segments across major U.S. Television networks. The T.V. platforms reach over 540 million homes both in the U.S. and international markets. The NEWSMAX - "New to The Street" show is syndicated on Sundays at 10-11 AM E.T. and broadcasted on Fox Business Network, Mondays and Tuesdays at 10:30 PM PT. FMW is also one of the nation's largest buyers of linear Television long and short-form - https://www.newsmaxtv.com/Shows/New-to-the-Street and https://www.newtothestreet.com/ .
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
FAQ
What is PetVivo Holdings' recent digital media campaign?
How many commercials will PetVivo broadcast monthly?
When is Spryng™ expected to be commercially available?
What therapeutic issues does Spryng™ address?
Which networks will feature PetVivo's commercials?
